Hospitalized cancer patients with opioid dependence stayed in the hospital longer and developed bloodstream infections more often than patients without the condition, according to a study published Sept. 5 in Medical Oncology. Researchers at the University at Buffalo (N.Y.) and…

Four therapies have reshaped the outlook across oncology and metabolic disease in recent months. Two have already won FDA approval: a first-of-its-kind breast cancer drug guided by blood-based mutation detection and the first targeted pill for pancreatic cancer. A third,…

Roivant’s experimental lung disease drug mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in a phase 2 trial of patients with pulmonary hypertension associated with interstitial lung disease, the highest PVR reduction reported in a randomized controlled pulmonary…

An AI-generated drug, rentosertib, being developed for idiopathic pulmonary fibrosis was associated with reductions in predicted biological age across six proteomic aging clocks, according to a study published Sept. 7 in Nature Biotechnology. Here are six things to know:

China is becoming a destination for U.S. patients seeking CAR-T cell therapy, according to a Sept. 6 report from The Wall Street Journal.  “China has basically done to CAR-T cell therapy the same thing that it’s done to other industries,…

On Sept. 4, Novartis announced that its experimental drug to prevent heart attack, strokes and cardiovascular death, pelacarsen, had failed.  “Lp(a)HORIZON was a pioneering cardiovascular outcomes trial designed to answer one of the most important unanswered questions in cardiovascular medicine…

American Regent has recalled three lots of Epinephrine Injection, USP, after leaking and cracked vials were found to contain particulate matter. The nationwide recall covers three lots of the 30 milligram/30 milliliter product, according to a Sept. 3 FDA news…

AstraZeneca’s tozorakimab is the first biologic to demonstrate statistically significant efficacy in reducing moderate and severe COPD exacerbations in a broad population of patients who continued to experience exacerbations while receiving inhaled standard-of-care therapy. Tozorakimab reduced moderate and severe COPD…

The FDA has granted accelerated approval to Etcamah (camizestrant), marking the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests show disease progression. Etcamah is used with…

The FDA has approved Zanvastro (zilganersen) injection to treat Alexander disease in pediatric and adult patients, making it the first FDA-approved treatment for the rare neurological disease. Zanvastro is also the first therapy to directly target the protein buildup that…